POTENTIAL CHINA LAUNCH: 2017
Uni-Bio's osteoporosis candidate achieves phase III endpoint
By Shannon Ellis
Thursday, July 3, 2014
SHANGHAI Hong Kong-based Uni-Bio Science Group Ltd. (HKSE:690) said Uni-PTH, an anabolic agent that builds bone mass in post-menopausal women suffering from osteoporosis, has achieved its primary endpoint in a phase III trial. Uni-PTH could be considered a biosimilar of Forteo (teriparatide, Eli Lilly and Co.). But since China has no pathway to prove biosimilarity, Uni-Bio took the drug through its paces as if it were a new drug.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.